Alamar Biosciences, Nightingale Health Launch Study to Measure Blood-Based Biomarkers for Neurodegenerative Disease

09:46 AM EST, 11/02/2026 (MT Newswires) -- Alamar Biosciences (ALMR) and Nightingale Health launched a UK Biobank vanguard study to measure blood-based biomarkers for neurodegenerative disease, the companies said Monday. The study will be conducted in Nightingale's laboratories using Alamar's NULISA platform, which will measure circulating protein biomarkers in 80,000 blood samples from UK Biobank participants, the companies said. Alzheimer's Research UK, LifeArc, and other partners funded the study, which is slated to be completed by the end of 2027, the companies added. Price: 30.25, Change: -0.35, Percent Change: -1.14